Vectorized Antibodies Market Outlook Strengthened by Innovation in Drug Delivery Platforms

The global vectorized antibodies market is poised for significant growth over the next decade, reflecting increasing adoption of advanced therapeutic antibodies and the rising prevalence of chronic and infectious diseases. According to recent market research, the market size is expected to reach US$ 4.9 billion in 2026 and is projected to grow to US$ 7.7 billion by 2033, representing a robust compound annual growth rate (CAGR) of 6.7% during the forecast period. This growth is fueled by continuous innovation in antibody engineering, the expansion of biopharmaceutical R&D, and growing applications of vectorized antibodies across oncology, infectious diseases, and autoimmune disorders.